Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Feb 1 2011

- Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile. The successful trial represents an important development milestone for Circassia's ToleroMune T-cell vaccine technology. The study was the first to use the company's commercial room-temperature-stable formulation, and provides confirmatory proof-of-concept for the final stage of development of its cat allergy T-cell vaccine.

"These clinical results are extremely good news, both for patients and for Circassia," said Steve Harris, Circassia's CEO. "By achieving a significant reduction in symptoms after just four doses, whilst also proving extremely well tolerated, our novel T-cell vaccine has demonstrated the true potential of ToleroMune to revolutionise allergy treatment. Our approach contrasts sharply with traditional immunotherapies, which can require dosing over a number of years under expert supervision due to the possibility of severe and even life-threatening reactions. These new clinical results, combined with our earlier successful phase II studies, scientifically validate both our ToleroMune technology and the commercial formulation we intend to progress into the final stage of development."

SOURCE Circassia